Aegis Therapeutics has announced that it has received New Zealand Patent No. 5937828 for fast acting formulations of triptans that can be administered as nasal, buccal, or sublingual sprays. The company’s Intravail formulations have been shown to reach therapeutic levels in the blood 20 to 30 times faster than currently marketed triptan tablets and nasal sprays.
The US Patent and Trade Office issued the first patent to Aegis for Intravail formulations of triptans in September 2012 and a second patent in May 2013.
Read the Aegis press release.
